Medico Remedies Ltd

Medico Remedies Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the accompanying limited review report. The meeting will also address any other business as permitted by the Chair. This meeting is a routine procedural step for the company to finalize and present its quarterly financial performance.

Medico Remedies Ltd has announced securing a significant government supply order valued at USD 1,406,450 (approximately INR 13.38 Crores) from PROMESE/CAL in the Dominican Republic. The order involves the supply of tablets, capsules, and dry syrups, with completion expected within three months. PROMESE/CAL is the national program responsible for centralized procurement and distribution of essential medicines and health supplies in the Dominican Republic. This international contract represents a key business development for Medico Remedies.

Medico Remedies Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut for all insiders, designated persons, and their immediate relatives starting from July 1st, 2026. It will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30th, 2026. This measure is standard practice to prevent potential misuse of unpublished price-sensitive information.

Medico Remedies Ltd has paid a total fine of ₹1,13,280 (₹56,640 each) to NSE and BSE for alleged non-compliance with Regulation 6(1) of the SEBI Listing Regulations for the period January 1 to February 17, 2026. The company received Show Cause Notices on May 20, 2026, and paid the fines on May 25, 2026. Medico Remedies stated that the non-compliance was inadvertently missed and assured future adherence. The company confirmed no material impact on its financials or operations.

Medico Remedies Ltd's board approved the audited standalone financial results for the quarter and year ended March 31, 2026. The board also approved the Board’s Report, Management Discussion Analysis (MDA), and Corporate Governance Report for FY26. Shah Shroff & Associates, Statutory Auditors, issued an audit report with an unmodified opinion on the financial statements.

Medico Remedies Ltd's Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, along with the auditor's report with an unmodified opinion from M/s. Shah Shroff & Associates. The board also approved the Board’s Report, Management Discussion Analysis (MDA), and Corporate Governance Report for the same financial year. The board meeting was held on May 21, 2026, commencing at 5:00 P.M and concluding at 5:25 P.M.

Medico Remedies Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will also address any other business with the chair's permission.

Medico Remedies Ltd received Statement of Penalties (SoP) notices from NSE and BSE on February 20, 2026, for alleged non-compliance with Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Each exchange levied a penalty of ₹63,720, totaling ₹127,440. The company's waiver applications, filed on February 24, 2026, were rejected by both BSE and NSE. Medico Remedies has since paid the requisite fines and confirmed compliance with Regulation 6(1) as of February 18, 2026. The company stated that there is no material impact on its financials, operations, or other activities.

Medico Remedies Ltd. has received a Show-Cause Notice (SoP) from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for alleged non-compliance of Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has been asked to pay a penalty of Rs. 63,720/- (inclusive of GST) by each NSE and BSE. The Company has filed a Waiver Application with respective exchanges on 24th February 2026. The alleged non-compliance does not have any material impact on the financials, operations, or other activities of the Company.

Medico Remedies Ltd, a WHO-GMP, ISO 9001-2015 & Government Recognised Star Export House, has appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer, Key Managerial Personnel of the Company. The appointment was made on 18th February 2026, as per the recommendations of the Nomination and Remuneration & Term of appointment Committee. Ms. Shah is an associate member of the Institute of Company Secretaries of India and has over 9+ Years of experience in dealing with secretarial compliances of Listed and Unlisted Companies.